Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 4Venous Thromboembolism 1Prostate Cancer Patients 1Pharmacokinetics of MDV3100 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Hematologic Neoplasms 1Cytochrome P450 Interaction 1Advanced Solid Tumor 1ALK-positive Advanced Tumors 1

Interventions

apixaban 5Rivaroxaban 5Dalteparin 4Enoxaparin 3edoxaban 2abelacimab 2Tinzaparin 2MAA868 2Heparin, Low-Molecular-Weight 2Dabigatran 2isoquercitrin 1calcium heparin 1betrixaban 1bemiparin 1Warfarin 1Heparin 1Gemcitabine 1Fondaparinux 1AVE 5026 1ALT-836 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Venous Thromboembolism × Warfarin × Clear all
NCT01130025 2025-02-24

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

LEO Pharma

Phase 3 Completed
900 enrolled
Classical hematology

Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡